A metastatic prostate cancer diagnosis and its treatments carry significant morbidity and related unmet supportive care needs. Such unmet needs have a profound decrement on patients and their families. We aimed to deliver at multimodal intervention based approach that targeted unmet needs for men and their partner/carers and compared this to current standard care.
INTRODUCTION AND OBJECTIVES:
A metastatic prostate cancer diagnosis and its treatments carry significant morbidity and related unmet supportive care needs. Such unmet needs have a profound decrement on patients and their families. We aimed to deliver at multimodal intervention based approach that targeted unmet needs for men and their partner/carers and compared this to current standard care.
METHODS: A two arm randomised controlled feasibility trial compared standard care to a multimodal supportive care intervention that combined an educational seminar on prostate cancer thrivership and individualized care from a designated prostate cancer specialist nurse. This involved in-depth assessment using patient reported outcome measures (PROMs) in routine clinical practice, followed up with a tailored plan of ongoing support to address informational, emotional, social and practical needs. 38 participants and 10 carers/ partners completed validated and reliable self-reported measures at baseline and at 3 months. 32 Semi-structured interviews were conducted with men, carers/partners and members of the multidisciplinary team. Self-efficacy was included as the potential moderator/mediator of intervention effect. Primary outcomes are unmet supportive care needs and quality of life. An economic evaluation was conducted alongside the randomised trial.
RESULTS: 29 participants in standard care arm (age 77.5, SD 6.2 years) identified a range of unmet supportive care needs related to physical, psychological/emotional, intimacy/sexual, practical, health system/informational, existential and patient/clinician communication needs. 19 participants (age 74.9, SD 8.2, years) in the interventions group, reported overall high satisfaction with the intervention and acceptance of PROMs in routine clinical practice, with less prevalence of unmet needs compared to standard care over time. Men and carers/ partners perceived that they had derived benefit from this model of care. Certain themes clearly emerged as important for participants, including being listened to by someone who could facilitate emotional expression, being provided with individually tailored information and receiving practical help and evidence-based advice for managing the consequences of cancer and its associated treatments. Significant cost-savings emerged in favour of the intervention.
CONCLUSIONS: This study has demonstrated that a multimodality supportive care intervention for men and their carer/partners affected by metastatic prostate cancer can achieve optimal supportive care. The active components of the intervention have been distinguished and provide the basis for the development of a larger sufficiently powered trial. One of the factors that may contribute to the slow progress in eliminating prostate cancer disparities among Black men is their underrepresentation in randomized controlled trials (RCTs) of new treatment modalities. We conducted this study to assess the current status of Black men's participation in RCTs for prostate cancer.
Source of
METHODS: We performed a protocol-driven systematic review for all published prostate cancer RCTs over a 25-year time period searching PUBMED. We only included RCTs of patients with an established diagnosis of prostate cancer and excluded studies of screening and diagnosis. For studies that resulted in multiple publications, only the initial study was included. We excluded secondary and subgroup analyses.
RESULTS: We found 584 unique trials that met the inclusion criteria, which we analyzed by type of intervention, sample size, disease stage, number of sites, origin, type of funding, publication year, the year enrollment began, and whether the study reported the inclusion of Black men. The median sample size of all trials was 125.5 (IQR ¼ 60-286.5) and the median number of sites was 5 (IQR ¼ 1-22). One hundred and eleven of the 584 (19.0%) trials worldwide and 81 of 189 (42.9%) of trials conducted exclusively within the US reported the enrollment of Black men. Of those trials that reported the inclusion of Black men, the median percentage of the study population was 10.55% overall (IQR ¼ 6.6%-19.8%) and 12.27% (IQR ¼ 7.0%-21.2%) for studies based exclusively in the United States. Among the 111 trials that reported the racial composition of participants, the median number of Black patients was 20 (IQR ¼ 8-37.5). In studies conducted exclusively within the US, the median number of black patients was 17 (IQR ¼ 8-31).
CONCLUSIONS: Less than 1 in 5 studies globally and half of studies from the US reported the participation of Black men. We found no study that enrolled Black men exclusively or that prospectively stratified analysis based on race. There is a critical need for greater involvement and better reporting of Black men's participation in prostate cancer trials. Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 THE JOURNAL OF UROLOGY â e195
Source of Funding: Departmental, NIH (U54MD008620)
PD09-06 CAN A SIMPLE COUNT OF SEVERAL COMMON COMORBIDITIES ACCURATELY PREDICT LONG-TERM, OTHER CAUSE MORTALITY IN MEN WITH PROSTATE CANCER?
Kian Asanad*, Los Angeles, CA; Douglas Skarecky, Thomas Ahlering, Irvine, CA; Stephen Freedland, Timothy Daskivich, Los Angeles, CA INTRODUCTION AND OBJECTIVES: Physicians need practical methods to accurately estimate life expectancy when counseling older men with comorbidities regarding treatment of prostate cancer. Although numerous nomograms exist for prediction of life expectancy (LE), few are used in practice due to the difficulty of integration into busy clinical workflows. We sought to determine if survival could be accurately predicted if reduced to a count of several common comorbidities that pose a high risk to mortality. In selecting these comorbidities, we aimed to balance frequency and risk in order to maximize identification of men at risk for overtreatment based on <10-year LE.
METHODS: We sampled 1,598 men with newly diagnosed prostate cancer at two Southern California Veterans Affairs Medical Centers from 1998 to 2004. We created rank-ordered lists of comorbidities organized by frequency and highest risk of mortality. Separate ranked lists were then created by differentially weighting comorbidities by frequency to risk ratios: 1:6, 1:4, 1:2, 1:1, 2:1, 4:1, and 6:1. By successively adding comorbidities from highest-to tenth highestranked, a set of 10 candidate comorbidity indices was constructed for each list. Using competing risks regression analysis, we determined cindex, the number of men with <10-year LE, and the number of men with <10-year LE treated with surgery or radiation for each index.
RESULTS: Candidate comorbidity indices heavily weighted by frequency were poor at identifying men with <10-year LE, while indices heavily weighted by risk of mortality failed to identify men who were overtreated. Six candidate indices each found more than 300 men with <10-year LE (range 303-392); all six were weighted either 2:1, 1:1, or 1:2 by frequency to risk ratio and included highly similar comorbidities. Two of the six indices identified more than 200 men with <10-year LE overtreated with surgery or radiation (range 173-203). The candidate index with the highest number overtreated was weighted 1:1 by frequency to risk and included six comorbidities: 1) chronic obstructive pulmonary disease 2) congestive heart failure 3) peripheral vascular disease 4) stroke 5) myocardial infarction 6) exertional angina. C-index for this index was 0.66.
CONCLUSIONS: A simple count of six comorbidities predicts the risk of 10-year other-cause mortality and robustly identifies men who are overtreated for early stage prostate cancer. Simplifying estimation of life expectancy may be key to operationalizing this critical variable for prostate cancer decision-making.
Source of Funding: None

PD09-07 THE IMPACT OF SHARED DECISION MAKING SOFTWARE ON DECISIONAL QUALITY OF MEN UNDERGOING TREATMENT FOR BPH: AN INTERIM ANALYSIS
Matthew Pollard*, Joseph Shirk, Casey Pagan, Sylvia Lambrechts, Lorna Kwan, Christopher Saigal, Los Angeles, CA INTRODUCTION AND OBJECTIVES: Shared decision making (SDM) allows patients and physicians to develop a treatment plan together by thoroughly exploring clinical risks and benefits in the setting of patient-specific values and concerns. This method of counseling can help to reduce decisional conflict, which has been identified as an indicator of decisional quality. Using novel SDM software, we aimed to examine the impact of shared decision making interventions on decisional conflict in patients seeking treatment for benign prostatic hyperplasia (BPH).
METHODS: All new patients evaluated for BPH were offered SDM software before their initial urologic visit either in person or by phone. Willing participants utilized the software at home or in the waiting area prior to their visit. The software provides education, preference assessment for relevant outcomes, and personalized decision analysis for the patient. A report from the software is sent to the counseling urologist and the patient. Following consultation with a urologist, patients completed a follow up questionnaire measuring disease-specific knowledge, satisfaction with care, and decisional conflict using the validated SURE scale (SURE¼4, high decisional quality; SURE¼ 0-3, low decisional quality). Questionnaire results were compared to baseline data collected from patients who did not receive the SDM module.
RESULTS: Data was available for 35 men in the SDM pilot group and 103 men from the control group. They were well matched in demographics and health literacy. Among all participants, significantly fewer men in the SDM group felt unsure regarding treatment options (12% vs 37%, p ¼ 0.0059) and were more likely to have made a shared decision (SDM score 1.87 vs 2.19, p¼0.0503). There was no significant difference in overall SURE score between control and pilot study participants (3.0 vs 2.7, p¼0.3). Among participants who reported some decisional conflict (n¼76), SDM pilot study participants were more likely to report adequate support to make a treatment choice than the control participants (82% vs 57%, p ¼ 0.0564).
CONCLUSIONS: Our interim analysis of a novel SDM intervention for men with BPH shows an improvement in understanding treatment options and shared decision making. The SDM software provided additional support among those patients who felt some e196 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 
